Index Vol. 97, 2007 Contents Keywords Authors · Index Vol. 97, 2007 Contents Keywords Authors ... Carl-Erik Dempfle, ... Non-homologous recombination associated with a shortened

http://www.thrombosis-online.com

Index Vol. 97, 2007 Contents Keywords

Authors

EditorEditorEditorEditor----inininin----Chief:Chief:Chief:Chief: Klaus T. Preissner, Germany Editorial Board:Editorial Board:Editorial Board:Editorial Board: Marie-Christine Alessi, France Peter Andreasen, Denmark Hellmut Augustin, Germany Lina Badiman, Spain Omar Benzakour, France Francesco Bernardi, Italy Thomas Bugge, U.S.A. Douglas Cines, U.S.A. Raffele de Caterina, Italy Hans Deckmyn, Belgium Paul Declerck, Belgium Carl-Erik Dempfle, Germany Mieke Dewerchin, Belgium Vincent Ellis, United Kingdom Bernd Engelmann, Germany Desmond Fitzgerald, Ireland Pablo Garcia de Frutos, Spain Regine Heller, Germany Matthias Herrmann, Germany Emilio Hirsch, Italy Kurt Huber, Austria Shaun Jackson, Australia Nelly Kieffer, Luxemburg Irene Lang, Austria Gregory Y. H. Lip, United Kingdom Raymund Machovich, Hungary Nigel Mackman, U.S.A. Christine Mannhalter, Austria Leonid Medved, U.S.A. Michael W. Mosesson, U.S.A. Frederick Ofosu, Canada Johannes Oldenburg, Germany Karlheinz Peter, Australia Thomas Podor, Canada Alvin Schmaier, U.S.A. Manfred Schmitt, Germany Wolfgang Siess, Germany Victor W. M. van Hinsbergh, The Netherlands Freek W. A. Verheugt, The Netherlands Johannes Waltenberger, The Netherlands Ulrich Walter, Germany Jean L. Wautier, France Artur-Aron Weber, Germany Christian Weber, Germany Hartmut Weiler, U.S.A. Jeffrey Weitz, Canada

Jaap Jan Zwaginga, The Netherlands

CONTENTS – Thrombosis and Haemostasis 2007; 97 (1-6)

II http://www.thrombosis-online.com

EDITORIAL FOCUS Thrombosis and Haemostasis: An interdisciplinary and translational endeavour K. T. Preissner .........................................................................................................................1 Antioxidative defense in endothelial cells: New kids on the block H. Morawietz ............................................................................................................................3 Alternatively spliced tissue factor – One cut too many? N. Mackman.............................................................................................................................5 Tissue factor-positive microparticles in blood associated with coagulopathy in cancer U. Rauch, S. Antoniak .............................................................................................................9 Retinal vein occlusion disease and platelet activation: Will antiplatelet therapy be a promising therapeutic strategy for patients with retinal vein occlusion disease in the future? S. Fateh-Moghadam, M. Gawaz..........................................................................................169 The clinical significance of circulating tissue factor in prostate cancer J. Nieva ................................................................................................................................329 Prevention of transient endothelial dysfunction in acute exercise: A friendly fire? T. Suvorava, G. Kojda .........................................................................................................331 Combined computed tomographic (CT)-angiography and indirect CT-venography for the diagnosis of pulmonary embolism: Is more scanning better? M. T. Grebe..........................................................................................................................501 Hormonal therapy with patch or pill: How much does it matter? K. Schaudig, C. Thomssen ..................................................................................................503

THEME ISSUE EDITORIAL FOCUS Signaling in endothelial cells: 10 years Department of Vascular Biology and Thrombosis Research at the Medical University Vienna B. R. Binder..........................................................................................................................334 Chemokines take centre stage in vascular biology C. Weber ..............................................................................................................................685

THEME ISSUE ARTICLES uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s view B. R. Binder, J. Mihaly, G. W. Prager ..................................................................................336 Protein C inhibitor, a serpin with functions in- and outside vascular biology M. Geiger .............................................................................................................................343 Inflammatory profile of oxidized phospholipids V. N. Bochkov ......................................................................................................................348 Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis E. Hofer, B. Schweighofer ...................................................................................................355


III http://www.thrombosis-online.com

Resolution of inflammation: Intracellular feedback loops in the endothelium G. Winsauer, R. de Martin ...................................................................................................364 Ubiquitylation within signaling pathways in- and outside of inflammation K. Hochrainer, J. Lipp ..........................................................................................................370 Fluorescent proteins and fluorescence resonance energy transfer (FRET) as tools in signaling research J. A. Schmid, A. Birbach ......................................................................................................378 Chemokines at large: In-vivo mechanisms of their transport, presentation and clearance I. G. Colditz, M. A. Schneider, M. Pruenster, A. Rot ...........................................................688 Transmembrane chemokines: Versatile ‘special agents’ in vascular inflammation A. Ludwig, C. Weber............................................................................................................694 Platelet-derived chemokines in vascular biology P. von Hundelshausen, F. Petersen, E. Brandt...................................................................704 The specific role of chemokines in atherosclerosis V. Braunersreuther, F. Mach, S. Steffens ...........................................................................714 Chemokines and thrombogenicity M. P. Lambert, B. S. Sachais, M. A. Kowalska ...................................................................722 Chemokines in vascular remodeling A. Schober, A. Zernecke......................................................................................................730 Chemokines in ischemia and reperfusion N. G. Frangogiannis.............................................................................................................738 Chemokines in cardiovascular risk prediction P. Aukrust, A. Yndestad, C. Smith, T. Ueland, L. Gullestad, J. K. Damås .........................748 Chemokines as mediators of angiogenesis B. Mehrad, M. P. Keane, R. M. Strieter ...............................................................................755 Three reactive compartments in venous malformations C. U. Ebenebe, S. Diehl, K. Bartnick, H. Dörge, J. Becker, L. Schweigerer, J. Wilting ......763

REVIEW ARTICLES Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance J. Siller-Matula, K. Schrör, J. Wojta, K. Huber ....................................................................385 The management of thrombosis in pregnancy: Role of low-molecular-weight heparin A. Kher, R. Bauersachs, J. D. Nielsen.................................................................................505 Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling J. Hänze, N. Weissmann, F. Grimminger, W. Seeger, F. Rose..........................................774 Vasa vasorum and atherosclerosis – Quid novi? A. C. Langheinrich, M. Kampschulte, T. Buch, R. M. Bohle................................................873


IV http://www.thrombosis-online.com

RAPID AND SHORT COMMUNICATIONS Alternatively spliced human tissue factor (asHTF) is not pro-coagulant P. Censarek, A. Bobbe, M. Grandoch, K. Schrör, A.-A. Weber ............................................11 Expression of the serine protease inhibitor neuroserpin in cells of the human myeloid lineage S. A. Kennedy, A. C. van Diepen, C. M. van den Hurk, L. C. Coates, T. W. Lee, L. L. Ostrovsky, E. Miranda, J. Perez, M. J. Davies, D. A. Lomas, P. R. Dunbar, N. P. Birch............................................................................................................................394 Circulating P-selectin and the risk of recurrent venous thromboembolism P. A. Kyrle, G. Hron, S. Eichinger, O. Wagner ....................................................................880

ORIGINAL ARTICLES

Blood Coagulation, Fibrinolysis and Cellular Haemostasis Rapid activation of haemostasis after hormonal emergency contraception M. van Rooijen, A. Silveira, S. Thomassen, L.-O. Hansson, J. Rosing, A. Hamsten, K. Bremme ........................................................................................................15 Relatively increased von Willebrand factor activity after off-pump coronary artery bypass graft surgery B. Lo, A. P. Nierich, C. J. Kalkman, R. Fijnheer ....................................................................21 Clot structure modification by fondaparinux and consequence on fibrinolysis: A new mechanism of antithrombotic activity R. Varin, S. Mirshahi, P. Mirshahi, G. Kierzek, D. Sebaoun,Z. Mishal, J.-P. Vannier, J. Yvonne Borg, G. Simoneau, C. Soria, J. Soria..................................................................27 No interaction between factor V Leiden and hyperhomocysteinemia or MTHFR 677TT genotype in venous thrombosis. Results of a meta-analysis of published studies and a large case-only study M. B. A. J. Keijzer, G. F. Borm, H. J. Blom, G. M. J. Bos, F. R. Rosendaal, M. den Heijer..........................................................................................................................32 Plasminogen binds to plasmin-modulated factor Xa by Ca2+- and C-terminal lysine-dependent and -independent interactions J. E. Grundy, M. A. Hancock, S. C. Meixner, R. C. MacKenzie, M. L. Koschinsky, E. L. G. Pryzdial .....................................................................................................................38 A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) – Part I: Pharmacological characterization Y.-X. Wang, L. Zhao, M. Nagashima, J. Vincelette, D. Sukovich, W. Li, B. Subramanyam, S. Yuan, K. Emayan, I. Islam, P. Hrvatin, J. Bryant, D. R. Light, R. Vergona, J. Morser, B. O. Buckman.....................................................................................................45 A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) – Part II: Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis Y.-X. Wang, V. da Cunha, J. Vincelette, L. Zhao, M. Nagashima, K. Kawai, S. Yuan, K. Emayan, I. Islam, J. Hosoya, M. E. Sullivan, W. P. Dole, J. Morser, B. O. Buckman, R. Vergona ..................................................................................................54 Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women A. Mavri, D. Bastelica, M. Poggi, P. Morange, F. Peiretti, M. Verdier,


V http://www.thrombosis-online.com

I. Juhan-Vague, M.-C. Alessi .................................................................................................62

High frequency of factor V Leiden in surgical patients with symptomatic venous thromboembolism despite prophylaxis M. Baba-Ahmed, G. Le Gal, F. Couturaud, K. Lacut, E. Oger, C. Leroyer .........................171 Severe haemophilia B due to a 6 kb factor IX gene deletion including exon 4: Non-homologous recombination associated with a shortened transcript from whole blood T.-C. Hsu, S. M. Nakaya, A. R. Thompson .........................................................................176 Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis E. L. E. de Bruijne, S. D. Murad, M. P. M. de Maat, M. W. T. Tanck, E. B. Haagsma, B. van Hoek, F. R. Rosendaal, H. L. A. Janssen, F. W. G. Leebeek, for the Liver and Thrombosis Study Group .........................................................................181 Venous thromboembolism during pregnancy or postpartum: Findings from the RIETE Registry A. Blanco-Molina, J. Trujillo-Santos, J. Criado, L. Lopez, R. Lecumberri, R. Gutierrez, M. Monreal, for the RIETE Investigators .............................................................................186 Accuracy of compression ultrasound in screening for deep venous thrombosis in acutely ill medical patients W. Z. Tomkowski, B. L. Davidson, J. Wisniewska, G. Malek, J. Kober, P. Kuca, B. Burakowska, K. Oniszh, A. Gallus, A. W. A. Lensing .....................................................191 Appropriateness of diagnostic strategies for evaluating suspected venous thromboembolism T. Arnason, P. S. Wells, A. J. Forster..................................................................................195 Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation D. D. Myers, Jr., S. K. Wrobleski, C. Longo, P. W. Bedard, N. Kaila, G. D. Shaw, F. J. Londy, S. E. Rohrer, B. A. Fex, P. J. Zajkowski, T. R. Meier, A. E. Hawley, D. M. Farris, N. E. Ballard, P. K. Henke, R. G. Schaub, T. W. Wakefield...........................400 Self-management of oral anticoagulation in the elderly: Rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial A. Siebenhofer, I. Rakovac, C. Kleespies, B. Piso, U. Didjurgeit........................................408 Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development K. Vretenbrant, S. Ramström, M. Bjerke, T. L. Lindahl .......................................................417 Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets E. I. Sinauridze, D. A. Kireev, N. Y. Popenko, A. V. Pichugin, M. A. Panteleev, O. V. Krymskaya, F. I. Ataullakhanov..................................................................................425 Soluble plasma-derived von Willebrand factor assembles to a haemostatically active filamentous network A. Barg, R. Ossig, T. Goerge, M. F. Schneider, H. Schillers, H. Oberleithner, S. W. Schneider ...................................................................................................................514 Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain A. Casonato, L. De Marco, L. Gallinaro, M. Sztukowska, M. Mazzuccato, M. Battiston, A. Pagnan, Z. M. Ruggeri ....................................................................................................527


VI http://www.thrombosis-online.com

ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens V. M. Morelli, M. C. H. de Visser, N. H. van Tilburg, H. L. Vos, J. C. J. Eikenboom, F. R. Rosendaal, R. M. Bertina............................................................................................534 Analysis of the novel factor X gene mutation Glu51Lys in two families with factor X-Riyadh anomaly A. Al-Hilali, K. Wulff, H. Abdel-Razeq, K. Abu Saud, F. Al-Gaili, F. H. Herrmann ..............542 Mutational screening of six afibrinogenemic patients: Identification and characterization of four novel molecular defects L. Monaldini, R. Asselta, S. Duga, F. Peyvandi, M. Karimi, M. Malcovati, M. L. Tenchini..546 Haemostatic changes related to fibrin formation and fibrinolysis during the first trimester in normal pregnancy and in recurrent miscarriage R. Marchi, Y. López Ramirez, C. Nagaswami, L. Masova, A. Pulido, J. López Mora, A. Muller, C. L. Arocha-Piñango, J. W. Weisel....................................................................552 Haemostatic activation in post-menopausal women taking low-dose hormone therapy: Less effect with transdermal administration? J. F. Brosnan, B. L. Sheppard, L. A. Norris .........................................................................558 Incidence and distribution of lower extremity deep venous thrombosis at indirect computed tomography venography in patients suspected of pulmonary embolism A. Nchimi, B. Ghaye, C. T. Noukoua, R. F. Dondelinger ....................................................566 The risk for thromboembolic disease in lupus anticoagulant patients due to pathways involving P-selectin and CD154 P. Bugert, I. Pabinger, K. Stamer, R. Vormittag, R. C. Skeate, M. M. Wahi, S. Panzer.....573 Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function. A comparative pharmacokinetic study I. Mahé, M. Aghassarian, L. Drouet, C. Bal dit-Sollier, K. Lacut, J.-J. Heilmann, D. Mottier, J.-F. Bergmann ..................................................................................................581 Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients G. Hu, D. Guo, N. S. Key, B. M. Conti-Fine ........................................................................788 Effect of staphylokinase-derived nonadecapeptide on the activation of plasminogen K. Okada, S. Ueshima, H. Matsuno, N. Kawao, C. Okamoto, M. Tanaka, O. Matsuo .......795 Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study A. Squizzato, E. Romualdi, E. Piantanida, V. E. A. Gerdes, H. R. Büller, M. Tanda, L. Bartalena, A. Venco, W. Ageno.......................................................................................803 The role of fibrin monomers in optimizing the diagnostic work-up of deep vein thrombosis R. E. G. Schutgens, F. J. L. M. Haas, M. J. Agterof, M. Vos, D. H. Biesma.......................807 Characterisation of five factor XI mutations M. J. Mitchell, L. Dai, J. B. Clarke, P. H. B. Bolton-Maggs, G. F. Savidge, A. Alhaq .........884 Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form V. Schroeder, J.-M. Vuissoz, A. Caflisch, H. P. Kohler .......................................................890


VII http://www.thrombosis-online.com

Calcium-binding sites of the thrombin-thrombomodulin-protein C complex: Possible implications for the effect of platelet factor 4 on the activation of vitamin K-dependent coagulation factors L. Yang, A. R. Rezaie ..........................................................................................................899 Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis A.E. Tsantes, G. K. Nikolopoulos, P. G. Bagos, E. Rapti, G. Mantzios, V. Kapsimali, A. Travlou.............................................................................................................................907 International Registry on Factor XIII Deficiency: A basis formed mostly on European data V. Ivaskevicius, R. Seitz, H. P. Kohler, V. Schroeder, L. Muszbek, R. A. S. Ariens, E. Seifried, J. Oldenburg and The Study Group..................................................................914 Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study E. J. Favaloro, J. Lloyd, J. Rowell, R. Baker, K. Rickard, G. Kershaw, A. Street, K. Scarff, G. Barrese, D. Maher, A. J. McLachlan...............................................................922 Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies W. D. Fisher, B. I. Eriksson, K. A. Bauer, L. Borris, O. E. Dahl, M. Gent, S. Haas, M. Homering, M. V. Huisman, A. K. Kakkar, P. Kälebo, L. M. Kwong, F. Misselwitz, A. G. G. Turpie.....................................................................................................................931 Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system A. L. Eilertsen, S. Liestøl, M.-C. Mowinckel, H. C. Hemker, P.-M. Sandset .......................938 Clinically suspected acute recurrent pulmonary embolism: A diagnostic challenge M. Nijkeuter, H. Kwakkel- van Erp, M. Söhne, L. W. Tick, M. J. H. A. Kruip, E. F. Ullmann, M. H. H. Kramer, H. R. Büller, M. H. Prins, F. W. G. Leebeek, M. V. Huisman on behalf of the Christopher Study Investigators .......................................944 Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies M. Sanmarco, S. Gayet, M.-C. Alessi, M. Audrain, E. de Maistre, J.-C. Gris, P. G. de Groot, E. Hachulla, J.-R. Harlé, P. Sié, M.-C. Boffa..............................................949

Platelets and Blood Cells Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles D. M. Smalley, K. E. Root, H. J. Cho, M. M. Ross, K. Ley ....................................................67 Tissue factor-enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa I. Lopez-Vilchez, G. Escolar, M. Diaz-Ricart, B. Fuste, A. M. Galan, J. G. White ..............202 Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome T. Cuisset, C. Frere, J. Quilici, P.-E. Morange, N. Saut, M. Romero-Barra, L. Camoin, M. Lambert, I. Juhan-Vague, J.-L. Bonnet, M.-C. Alessi.....................................................212


VIII http://www.thrombosis-online.com

Platelet activation by collagen is increased in retinal vein occlusion G. Leoncini, D. Bruzzese, M. G. Signorello, U. Armani, A. Piana, D. Ghiglione, P. Camicione..................................................................................................218 Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia F. Heidel, D. B. Lipka, C. von Auer, C. Huber, I. Scharrer, G. Hess...................................228 Glycoprotein Iba inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques S. M. Penz, A. J. Reininger, O. Toth, H. Deckmyn, R. Brandl, W. Siess............................435 Plasma membrane Ca2+-ATPase associates with CLP36, α-actinin and actin in human platelets L. D. Bozulic, M. T. Malik, D. W. Powell, A. Nanez, A. J. Link, K. S. Ramos, W. L. Dean ...........................................................................................................................587 Monocyte IL-10 produced in response to lipopolysaccharide modulates thrombin generation by inhibiting tissue factor expression and release of active tissue factor-bound microparticles S. Poitevin, E. Cochery-Nouvellon, A. Dupont, P. Nguyen .................................................598 Critical temperature ranges of hypothermia-induced platelet activation: Possible implications for cooling patients in cardiac surgery A. Straub, M. Breuer, H. P. Wendel, K. Peter, K. Dietz, G. Ziemer ....................................608 Sequential adhesion of platelets and leukocytes from flowing whole blood onto a collagen-coated surface: Requirement for a GpVI-binding site in collagen L. M. Butler, T. Metson-Scott, J. Felix, A. Abhyankar, G. E. Rainger, R. W. Farndale, S. P. Watson, G. B. Nash ....................................................................................................814 Inhibition of thrombin-induced platelet aggregation using human single-chain Fv antibodies specific for TREM-like transcript-1 B. Giomarelli, V. A. Washington, M. M. Chisholm, L. Quigley, J. B. McMahon, T. Mori, D. W. McVicar ......................................................................................................................955 Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood N. Maugeri, G. Di Fabio, M. Barbanti, G. de Gaetano, M. B. Donati, C. Cerletti ................965 Hyperresponsiveness of platelets in ischemic stroke S. Fateh-Moghadam, P. Htun, B. Tomandl, D. Sander, K. Stellos, T. Geisler, H. Langer, K. Walton, R. Handschu, C. Garlichs, W. G. Daniel, M. Gawaz .......................974

Wound Healing and Inflammation/Infection Danaparoid sodium reduces ischemia/reperfusion-induced liver injury in rats by attenuating inflammatory responses N. Harada, K. Okajima, H. Kohmura, M. Uchiba, T. Tomita..................................................81 Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy M. P. M. de Maat, J. S. Madsen, B. Langdahl, E. M. Bladbjerg, C. L. Tofteng, B. Abrahamsen, L. Rejnmark, K. Brixen, K. Christensen, J. Jespersen, S. R. Kristensen ...................................................................................................................234


IX http://www.thrombosis-online.com

Sex-specific, independent associations of insulin resistance with erythrocyte sedimentation rate in apparently healthy subjects A. López-Bermejo, I. Hernández-Aguado, I. J. Vera, M. Recasens, E. Esteve, R. Casamitjana, W. Ricart, J. M. Fernández-Real ..............................................................240 Fibronectin-binding proteins and clumping factor A in Staphylococcus aureus experimental endocarditis: FnBPA is sufficient to activate human endothelial cells R. Heying, J. van de Gevel, Y.-A. Que, P. Moreillon, H. Beekhuizen.................................617 Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection D. Sosothikul, P. Seksarn, S. Pongsewalak, U. Thisyakorn, J. Lusher ..............................627 Fibrinogen and fibrin induce synthesis of proinflammatory cytokines from isolated peripheral blood mononuclear cells T. Jensen, P. Kierulf, P. M. Sandset, O. Klingenberg, G. B. Joø, H. C. Godal, O. H. Skjønsberg .................................................................................................................822

Endothelium and Vascular Development Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: A novel antioxidative mechanism V. Nascimento-Silva, M. A. Arruda, C. Barja-Fidalgo, I. M. Fierro ........................................88 Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression Y. Feng, F. vom Hagen, F. Pfister, S. Djokic, S. Hoffmann, W. Back, P. Wagner, J. Lin,U. Deutsch, H.-P. Hammes..........................................................................................99 Thrombin activation of endometrial endothelial cells: A possible role in intrauterine growth restriction G. Krikun, S.-T. J. Huang, F. Schatz, C. Salafia, C. Stocco, C. J. Lockwood.....................245 Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): Regulation of ALK-1/endoglin pathway in endothelial cells A. Fernandez-L., E. M. Garrido-Martin, F. Sanz-Rodriguez, J.-R. Ramirez, C. Morales-Angulo, R. Zarrabeitia, A. Perez-Molino, C. Bernabéu, L.-M. Botella ..............254 Acute tissue-type plasminogen activator release in human microvascular endothelial cells: The roles of Gαq, PLC-γ, IP3 and 5,6-epoxyeicosatrienoic acid J. A. S. Muldowney III, C. A. Painter, E. Sanders-Bush, N. J. Brown, D. E. Vaughan .......263 Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication P. Gresele, R. Migliacci, A. Procacci, P. De Monte, E. Bonizzoni ......................................444 Regulation by DDAH/ADMA pathway of lipopolysaccharide-induced tissue factor expression in endothelial cells H.-Y. Xin, D.-J. Jiang, S.-J. Jia, K. Song, G.-P. Wang, Y.-J. Li, F.-P. Chen .......................830 Crucial roles of GATA-2 and SP1 in adrenomedullin-affected expression of tissue factor pathway inhibitor in human umbilical vein endothelial cells exposed to lipopolysaccharide W. Liu, Z.-Q. Zhu, W. Wang, S.-Y. Zu, G.-J. Zhu................................................................839


X http://www.thrombosis-online.com

Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: Involvement of peroxisome proliferator-activated receptor-γ and transforming growth factor-β1 S. Redondo, M. Hristov, D. Gümbel, T. Tejerina, C. Weber ...............................................979 Nuclear factor of activated T cells and early growth response-1 cooperate to mediate tissue factor gene induction by vascular endothelial growth factor in endothelial cells G. Schabbauer, B. Schweighofer, D. Mechtcheriakova, M. Lucerna, B. R. Binder, E. Hofer ................................................................................................................................988

Cardiovascular Biology and Cell Signalling Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastographystudy on whole blood K. Konstantinidis, T. Gerasimidis, E. Verdy, I. Elalamy, M. M. Samama, G. T. Gerotziafas..................................................................................................................109 The F11 receptor (F11R/JAM-A) in atherothrombosis: Overexpression of F11R in atherosclerotic plaques A. Babinska, B. M. Azari, M. O. Salifu, R. Liu, X.-C. Jiang, M. B. Sobocka, D. Boo, G. Al Khoury, J. S. Deitch, J. D. Marmur, Y. H. Ehrlich, E. Kornecki ..................................272 High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes T. Cuisset, C. Frere, J. Quilici, P.-E. Morange, L. Nait-Saidi, C. Mielot, L. Bali, M. Lambert, M.-C. Alessi, J.-L. Bonnet................................................................................282 Fibrinogen gene haplotypes in relation to risk of coronary events and coronary and extracoronary atherosclerosis: The Rotterdam Study I. Kardys, A. G. Uitterlinden, A. Hofman, J. C. M. Witteman, M. P. M. de Maat .................288 The –11377 C>G promoter variant of the adiponectin gene, prevalence of coronary atherosclerosis, and incidence of vascular events in men G. Hoefle, A. Muendlein, C. H. Saely, L. Risch, P. Rein, L. Koch, F. Schmid, S. Aczel, T. Marte, P. Langer, H. Drexel .............................................................................451 Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis Z. Vokó, Z. Bereczky, É. Katona, R. Ádány, L. Muszbek....................................................458 Factor XIII Val34Leu variant and the risk of myocardial infarction. A meta-analysis M. Shafey, J. L. Anderson, D. Scarvelis, S. P. Doucette, F. Gagnon, P. S. Wells .............635 Active endothelin is an important vasoconstrictor in acute coronary thrombi C. Adlbrecht, D. Bonderman, C. Plass, J. Jakowitsch, G. Beran, W. Sperker, P. Siostrzonek, D. Glogar, G. Maurer, I. M. Lang................................................................642 Protein disulphide isomerase-mediated LA419– NO release provides additional antithrombotic effects to the blockade of the ADP receptor G. Vilahur, E. Pena, T. Padró, L. Badimon..........................................................................650 Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans M. Watzka, A. Nebel, N. E. El Mokhtari, B. Ivandic, J. Müller, S. Schreiber, J. Oldenburg ........................................................................................................................998 Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery R. Wessely, B. Blaich, R. S. BelAiba, S. Merl, A. Görlach, A. Kastrati, A. Schömig ........1003


XI http://www.thrombosis-online.com

Cellular Proteolysis and Oncology Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer G. Hron, M. Kollars, H. Weber, V. Sagaster, P. Quehenberger,S. Eichinger, P. A. Kyrle, A. Weltermann ..................................................................................................119 Plasma tissue factor antigen in localized prostate cancer: Distribution, clinical significance and correlation with haemostatic activation markers F. Langer, F. K.-H. Chun, A. Amirkhosravi, M. Friedrich, S. Leuenroth, B. Eifrig, C. Bokemeyer, J. L. Francis ................................................................................................464 Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: Inhibitory effects on receptor-mediated uPA activity in vitro and in vivo J. Pass, A. Jögi, I. K. Lund, B. Rønø, M. G. Rasch, H. Gårdsvoll, L. R. Lund, M. Ploug, J. Rømer, K. Danø, G. Høyer-Hansen..............................................................1013 Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy F. Gieseler, I. Lühr, T. Kunze, C. Mundhenke, N. Maass, T. Erhart, M. Denker, D. Beckman, M. Tiemann, C. Schulte, P. Dohrmann, F. Cavaillé, F. Godeau, C. Gespach ........................................................................................................................1023 Thalidomide and thrombosis. A meta-analysis R. N. El Accaoui, W. A. Shamseddeen, A. T. Taher .........................................................1031

Animal Models Recombinant annexin-2 inhibits the progress of diabetic nephropathy in a diabetic mouse model via recovery of hypercoagulability H. Ishii, M. Hiraoka, A. Tanaka, K. Shimokado, M. Yoshida...............................................124 Immunization of LDL receptor-deficient mice with β2-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques S. Dunoyer-Geindre, B. R. Kwak, G. Pelli, I. Roth, N. Satta, R. J. Fish, G. Reber, F. Mach, E. K. O. Kruithof, P. de Moerloose .......................................................................129 Recombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding S. Charbonneau, F. Girard, D. Boudreault, M. Ruel, N. Blais, J.-F. Hardy.........................296 Coagulation and endothelial dysfunction during longterm hyperdynamic porcine bacteremia – effects of selective inducible nitric oxide synthase inhibition M. Matejovic, A. Krouzecky, J. Radej, R. Rokyta Jr., H. Kralova, P. Radermacher, I. Novak................................................................................................................................304 Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939) – an oral, direct factor Xa inhibitor B. J. Biemond, E. Perzborn, P. W. Friederich, M. Levi, U. Buetehorn, H. R. Büller ...........471 Remodeling of carotid arteries is associated with increased expression of thrombomodulin in a mouse transverse aortic constriction model Y.-H. Li, C.-Y. Hsieh, D. Ling Wang, H.-C. Chung, S.-L. Liu, T.-H. Chao, G.-Y. Shi, H.-L. Wu...............................................................................................................................658 Genetic strain differences in platelet aggregation and thrombus formation of laboratory rats T. Sudo, H. Ito, H. Hayashi, Y. Nagamura, K. Toga, Y. Yamada........................................665


XII http://www.thrombosis-online.com

A novel P2Y12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models Y.-X. Wang, J. Vincelette, V. da Cunha, B. Martin-McNulty, C. Mallari, R. M. Fitch, S. Alexander, I. Islam, B. O. Buckman, S. Yuan, J. M. Post, B. Subramanyam, R. Vergona, M. E. Sullivan, W. P. Dole, J. Morser, J. Bryant .............................................847 A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity – a staphylokinase variant. An in-vivo study J. Szemraj, A. Stankiewicz, W. Rozmyslowicz-SzermiÁska, A. Mogielnicki, A. Gromotowicz, W. Buczko, K. Oszajca, J. Bartkowiak, E. Chabielska ..........................1037

New Technologies, Diagnostic Tools and Drugs Design and characterization of dipetacompinR10H, a dipetalo-gastin II-derived, classical competitive thrombin inhibitor T. Bitter, M. López, G. Nowak..............................................................................................139 Simple and safe exclusion of pulmonary embolism in outpatients using quantitative D-dimer and Wells’ simplified decision rule R. J. Goekoop, N. Steeghs, R. W. L. M. Niessen, G. J. P. M. Jonkers, H. Dik, A. Castel, L. Werker-van Gelder, L. T. Vlasveld, R. C. J. van Klink, E. V. Planken, M. V. Huisman .....................................................................................................................146 Performance evaluation of the new CoaguChek XS system compared with the established CoaguChek system by patients experienced in INR-self management S. Braun, H. Watzke, J. M. Hasenkam, M. Schwab, T. Wolf, C. Dovifat, H. Völler ............310 Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity F. A. Kuypers, S. K. Larkin, J. J. Emeis, A. C. Allison.........................................................478 Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients M. U. Zafar, M. E. Farkouh, J. Osende, D. Shimbo, S. Palencia, J. Crook, R. Leadley, V. Fuster, J. H. Chesebro ....................................................................................................487 Multicentre ISI assignment and calibration of the INR measuring range of a new point-of-care system designed for home monitoring of oral anticoagulation therapy I. Leichsenring, W. Plesch, V. Unkrig, S. Kitchen, D. P. Kitchen, R. Maclean, B. Dikkeschei, A. M. H. P. van den Besselaar ....................................................................856

CASE REPORTS The importance of tissue factor source in the management of factor VII deficiency P. H. B. Bolton-Maggs, C. R. M. Hay, D. Shanks, M. J. Mitchell, J. H. McVey...................151 Coexistence of three genetic risk factors in a Spanish thrombophilic family: factor V Leiden, prothrombin 20210 and a new type I antithrombin deficiency A. Ordóñez, C. de Cos, A. Miñano, J. Rodríguez, D. Hernández-Espinosa, J. A. Muñoz, R. González-Conejero, V. Vicente, J. Corral..................................................153 Endothelial damage of the internal carotid artery after chemoradiotherapy of the neck for a Hodgkin lymphoma M. Di Nisio, M. Soesan, H.-M. Otten ...................................................................................315 Severe neutropenia under clopidogrel treatment three weeks after coronary stenting A. Schäfer, M. Eigenthaler, J. Bauersachs..........................................................................317


XIII http://www.thrombosis-online.com

A second report of platelet-type von Willebrand disease with a Gly233Ser mutation in the GPIBA gene P. Nurden, F. Lanza, C. Bonnafous-Faurie, A. Nurden.......................................................319 Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel non-responsive diabetic patient: Shall we routinely test platelet function? A. Schäfer, A. W. Bonz, M. Eigenthaler, J. Bauersachs .....................................................862 Factitious anticoagulant-resistance as a cause of recurrent arterial bypass graft occlusions B. Luxembourg, H. Mani, S. W. Toennes, G. Strubel, C. Klaeffling, G. Daemgen-von Brevern, C. Geisen, E. Lindhoff-Last ....................................................1046

LETTERS TO THE EDITOR Formation of mixed platelet-PMN leukocyte aggregates in the platelet function analyzer (PFA-100) device N. Maugeri, M. B. Donati, G. de Gaetano, C. Cerletti .........................................................156 IL-4 modulates tissue factor expression by human B lymphocytes in response to phorbol myristate acetate H. Mechiche, P. Nguyen ......................................................................................................158 The R2464C missense mutation in the von Willebrand factor gene causes a novel abnormality of multimer electrophoretic mobility and falls into the subgroup of type 2 von Willebrand disease 'unclassified' W. A. Lester, A. M. Guilliatt, M. S. Enayat, P. Rose, F. G. H. Hill.......................................159 Low soluble thrombomodulin activity and antigen is associated with a family history of heart disease while a high level is associated with a personal history of heart disease in type 2 diabetes C. J. Konstantoulas, J. A. Cooper, A.-K. Ohlin, S. E. Humphries, A. H. Goodall, C.-H. Toh, H. Mather, H. Ireland..........................................................................................161 Protein C deficiency screening using a thrombin-generation assay N. Hézard, L. Bouaziz-Borgi, M.-G. Remy, B. Florent, P. Nguyen......................................165 A further note on thrombosis in patients with homozygous beta thalassemia N. Akar .................................................................................................................................166 Fetal head impaction as a cause of iliofemoral phlebothrombosis: Contribution to the pathogenesis of deep vein thrombosis during pregnancy M. Terzic, O. Kontic-Vucinic ................................................................................................322 Quality control of CoaguChek test strips in the Netherlands A. M. H. P. van den Besselaar, M. M. C. L. Hoekstra, F. J. M. van der Meer ....................323 Evaluation of the AutoDimer D-dimer assay for the exclusion of pulmonary embolism M. J. H. A. Kruip, H. H. D. M. van Vliet, P. M. T. Pattynama, A. Kars, A. H. van den Meiracker, K.-S. G. Jie, F. W. G. Leebeek...................................................325 The effect of a thrombin exosite 2-binding DNA aptamer (HD-22) on non-catalytic thrombin-enhanced fibrin polymerization M. W. Mosesson ..................................................................................................................327 Prospective study of polymorphisms of the protein Z-dependent protease inhibitor and risk of venous thromboembolism A. R. Folsom, M. Cushman, L. J. Rasmussen-Torvik, S. R. Heckbert, M. Y. Tsai .............493


XIV http://www.thrombosis-online.com

Association of low protein Z levels with ischemic stroke in young women M. J. Heeb, M. Fisher, A. Paganini-Hill................................................................................495 Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids A. Gerhardt, R. B. Zotz, M. Stockschlaeder, R. E. Scharf...................................................496 Perioperative bridging with fondaparinux in a woman with antithrombin deficiency R. Bauersachs, S. Alban......................................................................................................498 Glycoprotein VI polymorphisms and outcome after percutaneous coronary interventions C. Boettiger, W. Koch, J. Mehilli, A. Schoemig, A. Kastrati.................................................673 Haemophilia patients exhibit prolonged coagulation time but normal lag time of thrombin generation test: Are these results really discordant? Y. Dargaud, J. C. Bordet, S. Francillon, C. Négrier.............................................................675 Fibrinogen Aα312 and Bβ448 polymorphisms are not related to bleeding during oral vitamin K-antagonist treatment A. A. Garcia, N. V. van der Hoeven, T. N. Boellaard, J. F. van der Heijden, A. P. A. Groot, P. H. Reitsma ..............................................................................................676 Influence of PROS1 gene mutations affecting protein S amino-acid 275 on plasma free protein S measurement M. Alhenc Gelas, F. Juin, E. de Raucourt, S. Gandrille, D. Borgel, M. Aiach.....................678 C-reactive protein and FcγRIIa functional polymorphisms are not associated with clinical presentation of stable and unstable angina A. Murphy, A. White, R. Nair, B. Kingwell, S. Duffy, J. Chin-Dusting, K. Woollard.............681 Nitric oxide synthase 3 genotypes and inflammatory markers in coronary artery disease patients W. Fergusson.......................................................................................................................683 Rebuttal: The independent association of nitric oxide synthase 3 polymorphisms and their combination with inflammatory markers I. Ikonomidis, J. Lekakis, M. Tsibida, D. T. Kremastinos.....................................................683 Any effect of CYP2C9 variants on warfarin clearance in Chinese patients? J. H. S. You, Z. Zuo, C. M. Y. Lo, L. Zhou, H. H. W. Yiu, C. T. S. Chau, K. C. Choi, D. K. M. Choi, R. S. M. Wong, G. Cheng ............................................................................866 Effects of hypolipemic drugs on the osteoprotegerin – sRANKL system in patients with coronary artery disease M. Celińska-Löwenhoff, T. Löwenhoff, A. Undas, P. Gluszko.............................................868 The Marburg I polymorphism of factor VII–activating protease and the risk of venous thromboembolism V. Weisbach, R. Ruppel, R. Eckstein ..................................................................................870 The growing impact of publications in haemostasis and thrombosis journals G. Lippi, M. Franchini.........................................................................................................1049 Improved visualisation of high-molecular-weight von Willebrand factor multimers D. J. Bowen, S. J. Bowley..................................................................................................1051


XV http://www.thrombosis-online.com

Age- and gender-related differences of plasma prothrombin activity levels T. Sakata, A. Okamoto, T. Morita, Y. Kokubo, K. Sato, A. Okayama, H. Tomoike, T. Miyata ............................................................................................................................1052 Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: Preliminary in-vitro findings M. Crescente, C. Cerletti, G. de Gaetano .........................................................................1054 Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin A. Undas, E. Placzkiewicz-Jankowska, L. Zieliński, W. Tracz ..........................................1056 Platelets and lipoprotein(a) in retinal vein occlusion: Mutual targets for aspirin therapy G. Lippi, M. Franchini, G. Targher .....................................................................................1059

KEYWORDS – Thrombosis and Haemostasis 2007; 97 (1-6)

XVI


4G/5G genetic polymorphism.... 907 A and B antigens....................... 534 ABO genotypes ......................... 534 acquired coagulation disorders.... 21 activated protein C .................... 938 activation ................................... 617 activation marker ....................... 890 activation peptide ...................... 890 acute coronary syndromes ........ 282 acute myocardial infarction........ 642 ADAMS/ADAMTS 13................. 627 adhesion.................... 694, 814, 979 ADP........................................... 847 ADP receptor antagonists ......... 435 ADP receptors ................... 212, 385 adrenomedullin.......................... 839 AIHA.......................................... 228 ALK-1 ........................................ 254 angiogenesis ............... 99, 755, 774 angiogenesis

and inhibitors . 245, 336, 355, 704 angiography....................... 451, 566 angioplasty ................................ 109 angiopoietin-2.............................. 99 angiotensin.................................. 88 animal models ........................... 400 annexins............................ 124, 478 anthrax toxin assay ................. 1013 antiphospholipid antibodies

....................................... 129, 949 antiphospholipid syndrome........ 949 antiplatelet activity ................... 1037 antiplatelet agents ..................... 212 anti-thrombosis therapy............. 955 antithrombotic treatment............ 109 APC resistance............................ 15 arterial remodeling..................... 658 arterial thrombosis... 296, 642, 1037 arteriogenesis............................ 774 aspirin........................................ 435 asymmetric dimethylarginine..... 830 atherosclerosis

...... 129, 272, 288, 336, 658, 694, 704, 714, 722, 748, 873

atherothrombosis....................... 272 ATL.............................................. 88 atomic force microscopy............ 514 beta2-glycoprotein 1.................. 129 biomarkers................................. 748 bleeding....................................... 54 blood coagulation ...................... 417 Budd-Chiari syndrome............... 181 calcitonin-gene related peptide ... 81 calcium ...................................... 899 calcium signaling ....................... 587 cancer ....................... 119, 464, 755 capsaicin-sensitive sensory

neurons.................................... 81 carboxypeptidases ...................... 45 cardiovascular disease................ 88 carotid artery disease ................ 109 case-control................................. 32

case-only .....................................32 CD154 .......................................573 CD4+ T cells ..............................788 CD-61 ........................................425 CD-62P......................................425 cell-cell interactions ...................608 chemokine receptor(s) .......722, 755 chemokine(s)

...... 694, 704, 714, 722, 730, 738, 748, 755, 763

chemoresistance .....................1023 chimeric protein .........................139 chondroitin sulfate .....................899 classical competitive kinetics .....139 clinical decision rule...................146 clinical studies/trials...146, 310, 949 clopidogrel resistance................385 clot elasticity ..............................417 clot structure ........................27, 552 CoaguChek................................856 coagulation 304, 487, 558, 617, 938 coagulation factor concentrate...922 coagulation factors ................11, 38 collagen .............................218, 814 collagen receptors .....................212 compression ultrasound (CUS)..191 computed tomography (CT)

.......................................566, 944 congenital afibrinogenemia........546 coronary artery disease .............451 coronary disease .......288, 458, 487 coronary heart disease ..............998 coronary syndrome....................212 C-reactive protein ......................234 cyclic flow variation....................847 cytokines....................................788 cytokines............245, 451, 788, 822 D-dimer..............................146, 807 D-dimer test ...............................195 decoy.........................................688 deep vein/venous thrombosis

(DVT) .............191, 400, 803, 807 deletion breakpoints...................176 dendritic cells.............................394 Dengue virus infection ...............627 diabetes mellitus................124, 240 diagnosis ...........................807, 944 diagnosis management..............146 diagnostic tests..........................195 DIC ............................................304 dimethylarginine

dimethylaminohydrolase ........830 dipetalogastin ............................139 dog.......................................54, 847 drug-eluting stent.....................1003 DSCR-1 .....................................988 ectopic mRNA............................176 EGR-1........................................988 elderly ................................408, 581 emigration..................................688 endocarditis ...............................617 endoglin .....................................254 endothelial .................................979

endothelial cell(s) ............................ 124, 254, 348, 355, 364, 370, 378, 627, 830, 988

endothelin / -receptors .............. 642 endothelium .................... 617, 1003 epidemiology..................... 288, 451 epoxyeicosatrienoic acids (EET’s)

.............................................. 263 erythrocyte sedimentation rate.. 240 estrogen.............................. 15, 234 exon 4 ............................... 176, 542 expression studies .................... 884 extracellular matrix.................... 763 F11 receptor ............................. 272 F11R......................................... 272 F11R/JAM-A ............................. 272 factor IX gene............................ 176 factor V Leiden.................... 32, 171 factor VIII .................................. 788 factor X ..................................... 425 factor Xa inhibitor ...................... 471 factor XI .................................... 884 factor XIII .................................. 458 factor XIII .......................... 635, 890 factor X-Riyadh ......................... 542 fibrin .......................................... 822 fibrin monomer.......................... 807 fibrin network............................... 27 fibrinogen ...........234, 288, 546, 822 fibrinolysis

...........27, 54, 181, 254, 417, 558 fibronectin binding protein A ..... 617 filopodia .................................... 587 flow cytometry........................... 974 flow-mediated vasodilation........ 444 fondaparinux ............................... 27 FXIII deficiency ......................... 914 gene polymorphism .................. 748 genetic ...................................... 635 genetic variation........................ 234 genetics .................................... 288 genotyping ................................ 914 Gla-domain proteins.................... 38 GPIb.......................................... 435 growth factor(s) ................. 763, 979


XVII


haemophilia A ........................... 788 haemophilia B............................ 176 haemorrhage............................. 296 haemostasis ...... 119, 245, 478, 627 haplotype................................... 998 HHT........................................... 254 home monitoring........................ 310 homocysteine .............................. 32 hormone (replacement) therapy

....................................... 234, 938 human antibodies ...................... 955 human platelets ......................... 218 human umbilical vein endothelial

cells ....................................... 839 hypercoagulability................ 21, 124 hyperthyroidism......................... 803 hypothyroidism .......................... 803 hypoxia................................ 99, 774 immunization............................. 129 inflammation

62, 181, 240, 245, 348, 264, 370, 400, 714, 738, 748, 738, 748, 822, 873, 965 inflammatory thrombosis ........... 272 inhibitors.................................... 788 inhibitors of uPA-uPAR interaction

............................................. 1013 INR calibration........................... 856 INR-self management ............... 310 insulin sensitivity........................ 240 interceptor ................................. 688 interleukin-10............................. 598 intermittent claudication............. 444 internal fibrin lysis...................... 552 International FXIII Registry........ 914 intraplaque haemorrhage .......... 873 invasion and survival ............... 1023 ischemia .................................... 738 ischemia/reperfusion injury........ 444 ISI assignment........................... 856 large deletion............................. 546 leukocyte ........................... 688, 738 leukocyte function / activation.... 642 leukocyte recruitment ................ 714 leukocyte trafficking/recruitment 730 levonorgestrel.............................. 15 lipopolysaccharide..................... 830 lipoxin .......................................... 88 low-molecular-weight heparin

(LMWH) ......... 109, 505, 581, 965 Lupus anticoagulant .................. 573 macrophages ............................ 394 menopause................................ 558 meta-analysis .............. 32, 458, 635 metabolic syndrome .................... 62 metalloproteinases .................... 694 methylenetetrahydrofolate-

reductase................................. 32 microparticles ............ 119, 464, 598 molecular dynamics simulations 890 monocytes......................... 394, 598 mouse anti-mouse mAbs......... 1013 MTHFR........................................ 32 multiple myeloma .................... 1031

mutation.....................................542 mutational screening..................546 myocardial infarction..487, 635, 714 NAD(P)H oxidase ........................88 nadroparin .................................109 neovascularization.......................99 neutrophils .................................814 NFAT .........................................988 nitric oxide .................304, 444, 650 nuclear factor-kappaB................830 obesity .................................62, 240 oral anticoagulant(s) ..........310, 471 oral anticoagulation ...................408 orthopaedic surgery...........171, 931 oxidative stress..........................304 paclitaxel .................................1003 PAI-1....................................62, 907 PAR receptors ...........................417 PAR-1 ......................................1023 partial thromboplastin time.........542 patient education .......................310 patient self-testing .....................856 pericyte ........................................99 periprocedural myocardial

infarction ................................282 phage display ............................955 pharmacokinetics.................45, 922 pharmacology ....................263, 979 phenotyping ...............................914 phosphatidylethanolamine.........949 phosphatidylserine.....................425 phospholipids.............343, 348, 478 pioglitazone ...............................979 plaque........................................435 plasma membrane Ca2+-ATPase

...............................................587 plasminogen ..............................795 plasminogen (-fragments)............38 plasminogen activation ....795, 1013 plasminogen activator inhibitors 336 platelet activation.......................974 platelet activation markers ...........67 platelet adhesion .......................514 platelet aggregation ...665, 847, 974 platelet factor 4 ..........................899 platelet glycoproteins.................608 platelet immunology...................704 platelet pharmacology................385 platelet physiology .....................608 platelet reactivity........................282 platelet thrombus formation .......435 platelet(s)

119, 202, 425, 487, 587, 650, 722, 814 platelet-PMN aggregates...........965 PMBC ........................................822 PMPs.........................................425 point mutations ..........................546 point-of-care testing...................856 polymorphism(s) ................212, 458 portal vein thrombosis................181 potency........................................45 pregnancy..........186, 245, 505, 552

procoagulant activity ................. 425 prophylaxis........................ 186, 471 protease-activated receptor ...... 263 proteases .................................. 343 proteases / inhibitors................... 21 protein C ................................... 899 protein function / activity ............. 38 protein trafficking....................... 378 prothrombin time....................... 542 P-selectin ...................573, 880, 965 pulmonary embolism..146, 171, 566 pulmonary hypertension............ 774 rabbit........................................... 54 raloxifene .................................. 938 randomized controlled trial........ 408 rat.................................54, 665, 847 rational drug design .................. 139 receptor..................................... 688 recombinant activated human factor

VII.......................................... 296 recombinant protein ................ 1037 recurrence................................. 880 recurrent miscarriage ................ 552 recurrent pulmonary embolism.. 944 renal insufficiency ..................... 581 reperfusion................................ 738 restenosis ................................. 336 retinal vein occlusion................. 218 rFVIIa ........................................ 202 rheological properties................ 552 rheology .................................... 814 risk factor(s) .......171, 451, 635, 880 rituximab ................................... 228 rivaroxaban ....................... 471, 931 rs9923231................................. 998


XVIII


safety .......................................... 45 secretion / exocytosis .................. 67 selectivity..................................... 45 self-management....................... 408 sepsis ........................................ 304 serpin(s) ............................ 343, 394 SHBG .......................................... 15 shedding.................................... 694 signal transduction

............... 263, 355, 364, 370, 378 single chain fragments (scFvs).. 955 single nucleotide polymorphism 181 sirolimus .................................. 1003 site-directed mutagenesis ......... 884 small-molecule inhibitor of

p-selectin ............................... 400 smooth muscle cell(s)...... 730, 1003 soluble VWF.............................. 514 spatial dynamics of coagulation.425 splanchnic vein thrombosis ....... 181 Staphylococcus aureus ............. 617 staphylokinase........................... 795 statins........................................ 129 stem cells .................................. 730 stenting...................................... 282 strain difference......................... 665 stroke ........................................ 974 surgery .............................. 171, 608 synthetic peptide ....................... 795 TAFI ...................................... 45, 54 thalidomide.............................. 1031 thombolysis ................................. 54 thrombin .................. 263, 899, 1023 thrombin generation .......... 425, 598 thrombin inhibitor....................... 139 thrombin-activatable fibrinolysis

inhibitor .................................. 181 thromboelastography................. 109 thromboembolism.............. 566, 573 thrombolysis .............................. 795 thrombolytic agent ................... 1037 thrombomodulin................. 658, 899 thrombophilia............................. 505 thromboprophylaxis ................... 581 thrombosis

.. 11, 54, 487, 566, 642, 650, 722, 847, 949, 1031

thrombus formation ................... 665 thrombus resolution................... 400 thyroid autoimmunity ................. 803 tibolone...................................... 938 tissue factor (TF)

....... 109, 119, 202, 598, 830, 988 tissue factor / factor VII........ 11, 464 tissue factor pathway inhibitor ... 839 tissue plasminogen activator ..... 394 tissue-type plasminogen activator

............................................... 263 TNF ............................................. 81 TNFR1......................................... 62 total hip replacement ................. 931 total knee replacement .............. 931 traffic ......................................... 202 tranexamic acid ......................... 254

transcription factors ...................763 transcriptional factor ..................839 transdermal hormone therapy....558 transient ischemic attack ...........974 triggering receptors expressed on

myeloid cells (TREM)-like transcript-1 (TLT-1) ................955

TTP............................................228 ultrasonography.........................807 ULVWF multimers .....................514 uPAR knock-out mice ..............1013 urokinase / receptor...................336 vasa vasorum ............................873 vascular cell markers ...................67 vascular remodeling...................730 vasculogenesis ..........................774 VEGF.........................................988 veins ..........................................566 venography........................191, 566 Venous malformation.................763 venous thromboembolism (VTE)

..............171, 186, 191, 195, 807, 880, 907, 931

venous thrombosis ..471, 505, 1037 vesicles......................................202 vitamin K....................................998 VITRO..........................................32 VKORC1....................................998 von Willebrand disease / disorder

(VWD) ............................527, 922 von Willebrand factor (VWF)

.........................21, 527, 534, 922 vWF multimers...........................527 vWF processing.........................527 vWF proteolysis .........................527

AUTHORS – Thrombosis and Haemostasis 2007; 97 (1-6)

XIX


Abdel-Razeq, H......................... 542 Abhyankar, A............................. 814 Abrahamsen, B.......................... 234 Abu Saud, K. ............................. 542 Aczel, S. .................................... 451 Ádány, R.................................... 458 Adlbrecht, C............................... 642 Ageno, W................................... 803 Aghassarian, M. ........................ 581 Agterof, M.J. .............................. 807 Aiach, M. ................................... 678 Akar, N. ..................................... 166 Al Khoury, G. ............................. 272 Alban, S..................................... 498 Alessi, M.-C. .............. 212, 282, 949 Alexander, S.............................. 847 Al-Gaili, F................................... 542 Alhaq, A..................................... 884 Alhenc Gelas, M. ....................... 678 Al-Hilali, A.................................. 542 Allison, A.C................................ 478 Amirkhosravi, A. ........................ 464 Anderson, J.L. ........................... 635 Antoniak, S. ................................... 9 Ariens, R.A.S............................. 914 Armani, U. ................................. 218 Arnason, T................................. 195 Arocha-Piñango, C.L. ................ 552 Arruda, M.A. ................................ 88 Asselta, R.................................. 546 Ataullakhanov, F.I...................... 425 Audrain, M. ................................ 949 Aukrust, P.................................. 748 Azari, B.M.................................. 272 Baba-Ahmed, M. ....................... 171 Babinska, A. .............................. 272 Back, W....................................... 99 Badimon, L. ............................... 650 Baker, R. ................................... 922 Bal dit-Sollier, C......................... 581 Bali, L. ....................................... 282 Ballard, N.E. .............................. 400 Barbanti, M. ............................... 965 Barg, A. ..................................... 514 Barja-Fidalgo, C. ......................... 88 Barrese, G. ................................ 922 Bartalena, L. .............................. 803 Bartkowiak, J. .......................... 1037 Bartnick, K. ................................ 763 Battiston, M. .............................. 527 Bauer, K.A................................. 931 Bauersachs, J.................... 317, 862 Bauersachs, R................... 498, 505 Becker, J. .................................. 763 Beckman, D............................. 1023 Bedard, P.W.............................. 400 Beekhuizen, H. .......................... 617 BelAiba, R.S. ........................... 1003 Beran, G.................................... 642 Bereczky, Z. .............................. 458 Bergmann, J.-F.......................... 581 Bernabéu, C. ............................. 254 Bertina, R.M. ............................. 534

Biemond, B.J. ............................471 Biesma, D.H. .............................807 Binder, B.R. ...............334, 336, 988 Birbach, A. .................................378 Birch, N.P. .................................394 Bitter, T. .....................................139 Bjerke, M. ..................................417 Bladbjerg, E.M. ..........................234 Blaich, B. .................................1003 Blais, N. .....................................296 Blanco-Molina, A. ......................186 Blom, H.J. ....................................32 Bobbe, A......................................11 Bochkov, V.N.............................348 Boellaard, T.N............................676 Boettiger, C................................673 Boffa, M.-C. ...............................949 Bohle, R.M.................................873 Bokemeyer, C............................464 Bolton-Maggs, P.H.B. ........151, 884 Bonderman, D. ..........................642 Bonizzoni, E...............................444 Bonnafous-Faurie, C..................319 Bonnet, J.-L. ......................212, 282 Bonz, A.W..................................862 Boo, D........................................272 Bordet, J.C.................................675 Borg, Y.J......................................27 Borgel, D....................................678 Borm, G.F. ...................................32 Borris, L. ....................................931 Bos, G.M.J...................................32 Botella, L.-M. .............................254 Bouaziz-Borgi, L. .......................165 Boudreault, D.............................296 Bowen, D.J. .............................1051 Bowley, S.J..............................1051 Bozulic, L.D. ..............................587 Brandl, R....................................435 Brandt, E....................................704 Braun, S.....................................310 Braunersreuther, V. ...................714 Bremme, K...................................15 Breuer, M...................................608 Brixen, K. ...................................234 Brosnan, J.F. .............................558 Brown, N.J. ................................263 Bruzzese, D. ..............................218 Bryant, J. .............................45, 847 Buch, T. .....................................873 Buckman, B.O. ..............45, 54, 847 Buczko, W. ..............................1037 Buetehorn, U. ............................471 Bugert, P....................................573 Büller, H.R. ................471, 803, 944 Burakowska, B...........................191 Butler, L.M. ................................814 Caflisch, A. ................................890 Camicione, P. ............................218 Camoin, L. .................................212 Casamitjana, R. .........................240 Casonato, A...............................527 Castel, A. ...................................146

Cavaillé, F............................... 1023 Celińska-Löwenhoff, M. ............ 868 Censarek, P. ............................... 11 Cerletti, C.................156, 965, 1054 Chabielska, E.......................... 1037 Chao, T.-H. ............................... 658 Charbonneau, S........................ 296 Chau, C.T.S. ............................. 866 Chen, F.-P................................. 830 Cheng, G. ................................. 866 Chesebro, J.H. .......................... 487 Chin-Dusting, J. ........................ 681 Chisholm, M.M. ......................... 955 Cho, H.J...................................... 67 Choi, D.K.M............................... 866 Choi, K.C. ................................. 866 Christensen, K. ......................... 234 Chun, F.K.-H. ............................ 464 Chung, H.-C.............................. 658 Clarke, J.B. ............................... 884 Coates, L.C............................... 394 Cochery-Nouvellon, E. .............. 598 Colditz, I.G. ............................... 688 Conti-Fine, B.M. ........................ 788 Cooper, J.A............................... 161 Corral, J. ................................... 153 Couturaud, F............................. 171 Crescente, M........................... 1054 Criado, J. .................................. 186 Crook, J. ................................... 487 Cuisset, T.......................... 212, 282 Cushman, M.............................. 493 da Cunha, V........................ 54, 847 Daemgen-von Brevern, G. ...... 1046 Dahl, O.E. ................................. 931 Dai, L. ....................................... 884 Damås, J.K. .............................. 748 Daniel, W.G............................... 974 Danø, K................................... 1013 Dargaud, Y................................ 675 Davidson, B.L............................ 191 Davies, M.J. .............................. 394 de Bruijne, E.L.E. ...................... 181 de Cos, C.................................. 153 de Gaetano, G. ........156, 965, 1054 de Groot, P.G............................ 949 de Maat, M.P.M..........181, 234, 288 de Maistre, E............................. 949 De Marco, L. ............................. 527 de Martin, R. ............................. 364 de Moerloose, P........................ 129 De Monte, P. ............................. 444 de Raucourt, E. ......................... 678 de Visser, M.C.H....................... 534 Dean, W.L................................. 587 Deckmyn, H. ............................. 435 Deitch, J.S................................. 272 den Heijer, M............................... 32 Denker, M. .............................. 1023 Deutsch, U. ................................. 99 Di Fabio, G................................ 965 Di Nisio, M................................. 315 Diaz-Ricart, M. .......................... 202


XX


Didjurgeit, U............................... 408 Diehl, S...................................... 763 Dietz, K...................................... 608 Dik, H. ....................................... 146 Dikkeschei, B............................. 856 Djokic, S. ..................................... 99 Dohrmann, P. .......................... 1023 Dole, W.P. ........................... 54, 847 Donati, M.B........................ 156, 965 Dondelinger, R.F. ...................... 566 Dörge, H.................................... 763 Doucette, S.P. ........................... 635 Dovifat, C................................... 310 Drexel, H. .................................. 451 Drouet, L.................................... 581 Duffy, S. .................................... 681 Duga, S. .................................... 546 Dunbar, P.R............................... 394 Dunoyer-Geindre, S. ................. 129 Dupont, A. ................................. 598 Ebenebe, C.U............................ 763 Eckstein, R. ............................... 870 Ehrlich, Y.H. .............................. 272 Eichinger, S. ...................... 119, 880 Eifrig, B...................................... 464 Eigenthaler, M. .................. 317, 862 Eikenboom, J.C.J. ..................... 534 Eilertsen, A.L. ............................ 938 El Accaoui, R.N. ...................... 1031 El Mokhtari, N.E. ....................... 998 Elalamy, I................................... 109 Emayan, K............................. 45, 54 Emeis, J.J.................................. 478 Enayat, M.S............................... 159 Erhart, T. ................................. 1023 Eriksson, B.I. ............................. 931 Escolar, G.................................. 202 Esteve, E................................... 240 Farkouh, M.E............................. 487 Farndale, R.W. .......................... 814 Farris, D.M................................. 400 Fateh-Moghadam, S.......... 169, 974 Favaloro, E.J. ............................ 922 Felix, J. ...................................... 814 Feng, Y........................................ 99 Fergusson, W............................ 683 Fernandez-L., A......................... 254 Fernández-Real, J.M................. 240 Fex, B.A..................................... 400 Fierro, I.M. ................................... 88 Fijnheer, R................................... 21 Fish, R.J. ................................... 129 Fisher, M. .................................. 495 Fisher, W.D. .............................. 931 Fitch, R.M. ................................. 847 Florent, B................................... 165 Folsom, A.R............................... 493 Forster, A.J................................ 195 Franchini, M................... 1049, 1059 Francillon, S. ............................. 675 Francis, J.L................................ 464 Frangogiannis, N.G. .................. 738

Frere, C. ............................212, 282 Friederich, P.W..........................471 Friedrich, M................................464 Fuste, B. ....................................202 Fuster, V. ...................................487 Gagnon, F..................................635 Galan, A.M.................................202 Gallinaro, L. ...............................527 Gallus, A. ...................................191 Gandrille, S................................678 Garcia, A.A. ...............................676 Gårdsvoll, H.............................1013 Garlichs, C.................................974 Garrido-Martin, E.M. ..................254 Gawaz, M. .........................169, 974 Gayet, S.....................................949 Geiger, M...................................343 Geisen, C.................................1046 Geisler, T. ..................................974 Gent, M......................................931 Gerasimidis, T. ..........................109 Gerdes, V.E.A............................803 Gerhardt, A. ...............................496 Gerotziafas, G.T. .......................109 Gespach, C..............................1023 Ghaye, B....................................566 Ghiglione, D...............................218 Gieseler, F. ..............................1023 Giomarelli, B. .............................955 Girard, F. ...................................296 Glogar, D. ..................................642 Gluszko, P. ................................868 Godal, H.C.................................822 Godeau, F................................1023 Goekoop, R.J.............................146 Goerge, T. .................................514 González-Conejero, R. ..............153 Goodall, A.H. .............................161 Görlach, A................................1003 Grandoch, M................................11 Grebe, M.T. ...............................501 Gresele, P..................................444 Grimminger, F............................774 Gris, J.-C. ..................................949 Gromotowicz, A. ......................1037 Groot, A.P.A. .............................676 Grundy, J.E..................................38 Guilliatt, A.M. .............................159 Gullestad, L. ..............................748 Gümbel, D. ................................979 Guo, D. ......................................788 Gutierrez, R. ..............................186 Haagsma, E.B. ..........................181 Haas, F.J.L.M. ...........................807 Haas, S......................................931 Hachulla, E. ...............................949 Hammes, H.-P. ............................99 Hamsten, A..................................15 Hancock, M.A. .............................38 Handschu, R..............................974 Hansson, L.-O. ............................15 Hänze, J. ...................................774

Harada, N. .................................. 81 Hardy, J.-F. ............................... 296 Harlé, J.-R................................. 949 Hasenkam, J.M. ........................ 310 Hawley, A.E. ............................. 400 Hay, C.R.M. .............................. 151 Hayashi, H. ............................... 665 Heckbert, S.R............................ 493 Heeb, M.J. ................................ 495 Heidel, F. .................................. 228 Heilmann, J.-J. .......................... 581 Hemker, H.C. ............................ 938 Henke, P.K................................ 400 Hernández-Aguado, I................ 240 Hernández-Espinosa, D............ 153 Herrmann, F.H. ......................... 542 Hess, G..................................... 228 Heying, R. ................................. 617 Hézard, N.................................. 165 Hill, F.G.H. ................................ 159 Hiraoka, M................................. 124 Hochrainer, K. ........................... 370 Hoefle, G................................... 451 Hoekstra, M.M.C.L. ................... 323 Hofer, E............................. 355, 988 Hoffmann, S................................ 99 Hofman, A................................. 288 Homering, M. ............................ 931 Hosoya, J. ................................... 54 Høyer-Hansen, G.................... 1013 Hristov, M.................................. 979 Hron, G. ............................ 119, 880 Hrvatin, P. ................................... 45 Hsieh, C.-Y................................ 658 Hsu, T.-C. ................................. 176 Htun, P...................................... 974 Hu, G. ....................................... 788 Huang, S.-T.J............................ 245 Huber, C. .................................. 228 Huber, K.................................... 385 Huisman, M.V. ...........146, 931, 944 Humphries, S.E......................... 161 Ikonomidis, I.............................. 683 Ireland, H. ................................. 161 Ishii, H....................................... 124 Islam, I. ..........................45, 54, 847 Ito, H. ........................................ 665 Ivandic, B. ................................. 998 Ivaskevicius, V. ......................... 914 Jakowitsch, J. ........................... 642 Janssen, H.L.A.......................... 181 Jensen, T. ................................. 822 Jespersen, J.............................. 234 Jia, S.-J..................................... 830 Jiang, D.-J................................. 830 Jiang, X.-C. ............................... 272 Jie, K.-S.G................................. 325 Jögi, A..................................... 1013 Jonkers, G.J.P.M. ..................... 146 Joø, G.B.................................... 822 Juhan-Vague, I.......................... 212 Juin, F. ...................................... 678


XXI


Kaila, N. .................................... 400 Kakkar, A.K. .............................. 931 Kälebo, P................................... 931 Kalkman, C.J. .............................. 21 Kampschulte, M......................... 873 Kardys, I. ................................... 288 Karimi, M. .................................. 546 Kars, A. ..................................... 325 Kastrati, A........................ 673, 1003 Katona, É................................... 458 Kawai, K. ..................................... 54 Kawao, N................................... 795 Keane, M.P................................ 755 Keijzer, M.B.A.J........................... 32 Kennedy, S.A. ........................... 394 Kershaw, G................................ 922 Key, N.S. ................................... 788 Kher, A. ..................................... 505 Kierulf, P.................................... 822 Kierzek, G.................................... 27 Kingwell, B................................. 681 Kireev, D.A. ............................... 425 Kitchen, D.P. ............................. 856 Kitchen, S.................................. 856 Klaeffling, C. ............................ 1046 Kleespies, C. ............................. 408 Klingenberg, O. ......................... 822 Kober, J. .................................... 191 Koch, L. ..................................... 451 Koch, W..................................... 673 Kohler, H.P. ....................... 890, 914 Kohmura, H. ................................ 81 Kojda, G. ................................... 331 Kokubo, Y................................ 1052 Kollars, M. ................................. 119 Konstantinidis, K........................ 109 Konstantoulas, C.J. ................... 161 Kontic-Vucinic, O....................... 322 Kornecki, E. ............................... 272 Koschinsky, M.L. ......................... 38 Kowalska, M.A........................... 722 Kralova, H.................................. 304 Kramer, M.H.H. ......................... 944 Kremastinos, D.T....................... 683 Krikun, G. .................................. 245 Kristensen, S.R. ........................ 234 Krouzecky, A. ............................ 304 Kruip, M.J.H.A. .................. 325, 944 Kruithof, E.K.O. ......................... 129 Krymskaya, O.V. ....................... 425 Kuca, P...................................... 191 Kunze, T. ................................. 1023 Kuypers, F.A.............................. 478 Kwak, B.R.................................. 129 Kwakkel- van Erp, H.................. 944 Kwong, L.M. .............................. 931 Kyrle, P.A. ......................... 119, 880 Lacut, K............................. 171, 581 Lambert, M. ....................... 212, 282 Lambert, M.P............................. 722 Lang, I.M. .................................. 642 Langdahl, B. .............................. 234

Langer, F. ..................................464 Langer, H...................................974 Langer, P. ..................................451 Langheinrich, A.C. .....................873 Lanza, F.....................................319 Larkin, S.K. ................................478 Le Gal, G. ..................................171 Leadley, R. ................................487 Lecumberri, R. ...........................186 Lee, T.W....................................394 Leebeek, F.W.G. .......181, 325, 944 Leichsenring, I. ..........................856 Lekakis, J...................................683 Lensing, A.W.A..........................191 Leoncini, G. ...............................218 Leroyer, C..................................171 Lester, W.A................................159 Leuenroth, S. .............................464 Levi, M. ......................................471 Ley, K. .........................................67 Li, W. ...........................................45 Li, Y.-H.......................................658 Li, Y.-J. ......................................830 Liestøl, S....................................938 Light, D.R.....................................45 Lin, J. ...........................................99 Lindahl, T.L................................417 Lindhoff-Last, E. ......................1046 Ling Wang, D.............................658 Link, A.J.....................................587 Lipka, D.B. .................................228 Lipp, J. .......................................370 Lippi, G. .........................1049, 1059 Liu, R. ........................................272 Liu, S.-L. ....................................658 Liu, W. .......................................839 Lloyd, J. .....................................922 Lo, B. ...........................................21 Lo, C.M.Y...................................866 Lockwood, C.J. ..........................245 Lomas, D.A................................394 Londy, F.J..................................400 Longo, C. ...................................400 López Mora, J............................552 López Ramirez, Y. .....................552 Lopez, L.....................................186 López, M....................................139 López-Bermejo, A......................240 Lopez-Vilchez, I. ........................202 Löwenhoff, T..............................868 Lucerna, M.................................988 Ludwig, A...................................694 Lühr, I. .....................................1023 Lund, I.K. .................................1013 Lund, L.R. ................................1013 Lusher, J....................................627 Luxembourg, B. .......................1046 Maass, N. ................................1023 Mach, F..............................129, 714 MacKenzie, R.C...........................38 Mackman, N. .................................5 Maclean, R. ...............................856 Madsen, J.S...............................234

Mahé, I. ..................................... 581 Maher, D. .................................. 922 Malcovati, M.............................. 546 Malek, G. .................................. 191 Malik, M.T. ................................ 587 Mallari, C................................... 847 Mani, H. .................................. 1046 Marchi, R. ................................. 552 Marmur, J.D. ............................. 272 Marte, T. ................................... 451 Martin-McNulty, B. .................... 847 Masova, L. ................................ 552 Matejovic, M.............................. 304 Mather, H. ................................. 161 Matsuno, H................................ 795 Matsuo, O. ................................ 795 Maugeri, N. ....................... 156, 965 Maurer, G.................................. 642 Mazzuccato, M.......................... 527 McLachlan, A.J. ........................ 922 McMahon, J.B. .......................... 955 McVey, J.H................................ 151 McVicar, D.W............................ 955 Mechiche, H.............................. 158 Mechtcheriakova, D. ................. 988 Mehilli, J.................................... 673 Mehrad, B. ................................ 755 Meier, T.R. ................................ 400 Meixner, S.C. .............................. 38 Merl, S. ................................... 1003 Metson-Scott, T......................... 814 Mielot, C.................................... 282 Migliacci, R................................ 444 Mihaly, J.................................... 336 Miñano, A.................................. 153 Miranda, E. ............................... 394 Mirshahi, P.................................. 27 Mirshahi, S.................................. 27 Mishal, Z. .................................... 27 Misselwitz, F. ............................ 931 Mitchell, M.J. ..................... 151, 884 Miyata, T. ................................ 1052 Mogielnicki, A.......................... 1037 Monaldini, L............................... 546 Monreal, M. ............................... 186 Morales-Angulo, C. ................... 254 Morange, P.-E................... 212, 282 Morawietz, H. ................................ 3 Moreillon, P............................... 617 Morelli, V.M. .............................. 534 Mori, T....................................... 955 Morita, T.................................. 1052 Morser, J. .......................45, 54, 847 Mosesson, M.W. ....................... 327 Mottier, D. ................................. 581 Mowinckel, M.-C. ...................... 938 Muendlein, A............................. 451 Muldowney III, J.A.S. ................ 263 Muller, A.................................... 552 Müller, J. ................................... 998 Mundhenke, C......................... 1023 Muñoz, J.A. ............................... 153 Murad, S.D................................ 181 Murphy, A. ................................ 681


XXII


Muszbek, L. ....................... 458, 914 Myers Jr., D.D. .......................... 400 Nagamura, Y. ............................ 665 Nagashima, M. ...................... 45, 54 Nagaswami, C. .......................... 552 Nair, R. ...................................... 681 Nait-Saidi, L............................... 282 Nakaya, S.M.............................. 176 Nanez, A.................................... 587 Nascimento-Silva, V. ................... 88 Nash, G.B.................................. 814 Nchimi, A................................... 566 Nebel, A. ................................... 998 Négrier, C.................................. 675 Nguyen, P.................. 158, 165, 598 Nielsen, J.D. .............................. 505 Nierich, A.P. ................................ 21 Niessen, R.W.L.M. .................... 146 Nieva, J. .................................... 329 Nijkeuter, M. .............................. 944 Norris, L.A. ................................ 558 Noukoua, C.T. ........................... 566 Novak, I. .................................... 304 Nowak, G................................... 139 Nurden, A. ................................. 319 Nurden, P. ................................. 319 Oberleithner, H. ......................... 514 Oger, E...................................... 171 Ohlin, A.-K. ................................ 161 Okada, K. .................................. 795 Okajima, K................................... 81 Okamoto, A. ............................ 1052 Okamoto, C. .............................. 795 Okayama, A............................. 1052 Oldenburg, J.............................. 998 Oniszh, K................................... 191 Ordóñez, A. ............................... 153 Osende, J. ................................. 487 Ossig, R..................................... 514 Ostrovsky, L.L. .......................... 394 Oszajca, K. .............................. 1037 Otten, H.-M................................ 315 Pabinger, I. ................................ 573 Padró, T..................................... 650 Paganini-Hill, A.......................... 495 Pagnan, A.................................. 527 Painter, C.A. .............................. 263 Palencia, S. ............................... 487 Panteleev, M.A. ......................... 425 Panzer, S................................... 573 Pass, J. ................................... 1013 Pattynama, P.M.T...................... 325 Pelli, G....................................... 129 Pena, E. .................................... 650 Penz, S.M.................................. 435 Perez, J. .................................... 394 Perez-Molino, A......................... 254 Perzborn, E. .............................. 471 Peter, K. .................................... 608 Petersen, F................................ 704 Peyvandi, F. .............................. 546

Pfister, F. .....................................99 Piana, A. ....................................218 Piantanida, E. ............................803 Pichugin, A.V. ............................425 Piso, B. ......................................408 Placzkiewicz-Jankowska, E. ....1056 Planken, E.V..............................146 Plass, C. ....................................642 Plesch, W. .................................856 Ploug, M. .................................1013 Poitevin, S. ................................598 Pongsewalak, S.........................627 Popenko, N.Y. ...........................425 Post, J.M....................................847 Powell, D.W. ..............................587 Prager, G.W...............................336 Preissner, K.T................................1 Prins, M.H..................................944 Procacci, A. ...............................444 Pruenster, M. .............................688 Pryzdial, E.L.G.............................38 Pulido, A. ...................................552 Que, Y.-A...................................617 Quehenberger, P. ......................119 Quigley, L. .................................955 Quilici, J. ............................212, 282 Radej, J. ....................................304 Radermacher, P. .......................304 Rainger, G.E..............................814 Rakovac, I..................................408 Ramirez, J.-R.............................254 Ramos, K.S. ..............................587 Ramström, S..............................417 Rasch, M.G..............................1013 Rasmussen-Torvik, L.J. .............493 Rauch, U........................................9 Reber, G. ...................................129 Recasens, M..............................240 Redondo, S................................979 Rein, P.......................................451 Reininger, A.J. ...........................435 Reitsma, P.H. ............................676 Rejnmark, L. ..............................234 Remy, M.-G. ..............................165 Rezaie, A.R. ..............................899 Ricart, W....................................240 Rickard, K. .................................922 Risch, L......................................451 Rodríguez, J. .............................153 Rohrer, S.E................................400 Rømer, J..................................1013 Romero-Barra, M. ......................212 Romualdi, E. ..............................803 Rønø, B. ..................................1013 Root, K.E. ....................................67 Rose, F. .....................................774 Rose, P......................................159 Rosendaal, F.R............32, 181, 534 Rosing, J......................................15 Ross, M.M. ..................................67 Rot, A.........................................688 Roth, I. .......................................129

Rowell, J. .................................. 922 Rozmyslowicz-Szermińska, W.1037 Ruel, M. .................................... 296 Ruggeri, Z.M. ............................ 527 Ruppel, R.................................. 870 Sachais, B.S. ............................ 722 Saely, C.H................................. 451 Sagaster, V. .............................. 119 Sakata, T. ............................... 1052 Salafia, C. ................................. 245 Salifu, M.O. ............................... 272 Samama, M.M........................... 109 Sander, D.................................. 974 Sanders-Bush, E....................... 263 Sandset, P.M. ................... 822, 938 Sanmarco, M............................. 949 Sanz-Rodriguez, F. ................... 254 Sato, K. ................................... 1052 Satta, N..................................... 129 Saut, N...................................... 212 Savidge, G.F............................. 884 Scarff, K. ................................... 922 Scarvelis, D............................... 635 Schabbauer, G.......................... 988 Schäfer, A. ........................ 317, 862 Scharf, R.E................................ 496 Scharrer, I. ................................ 228 Schatz, F................................... 245 Schaub, R.G. ............................ 400 Schaudig, K............................... 503 Schillers, H................................ 514 Schmid, F.................................. 451 Schmid, J.A............................... 378 Schneider, M.A. ........................ 688 Schneider, M.F.......................... 514 Schneider, S.W......................... 514 Schober, A. ............................... 730 Schoemig, A.............................. 673 Schömig, A.............................. 1003 Schreiber, S. ............................. 998 Schroeder, V..................... 890, 914 Schrör, K............................. 11, 385 Schulte, C. .............................. 1023 Schutgens, R.E.G. .................... 807 Schwab, M. ............................... 310 Schweigerer, L. ......................... 763 Schweighofer, B................ 355, 988 Sebaoun, D................................. 27 Seeger, W................................. 774 Seifried, E. ................................ 914 Seitz, R. .................................... 914 Seksarn, P. ............................... 627 Shafey, M.................................. 635 Shamseddeen, W.A. ............... 1031 Shanks, D. ................................ 151 Shaw, G.D................................. 400 Sheppard, B.L. .......................... 558 Shi, G.-Y. .................................. 658 Shimbo, D. ................................ 487 Shimokado, K............................ 124 Sié, P. ....................................... 949 Siebenhofer, A. ......................... 408 Siess, W.................................... 435


XXIII


Signorello, M.G.......................... 218 Siller-Matula, J........................... 385 Silveira, A. ................................... 15 Simoneau, G. .............................. 27 Sinauridze, E.I. .......................... 425 Siostrzonek, P. .......................... 642 Skeate, R.C. .............................. 573 Skjønsberg, O.H........................ 822 Smalley, D.M. .............................. 67 Smith, C..................................... 748 Sobocka, M.B. ........................... 272 Soesan, M. ................................ 315 Söhne, M. .................................. 944 Song, K. .................................... 830 Soria, C. ...................................... 27 Soria, J. ....................................... 27 Sosothikul, D. ............................ 627 Sperker, W. ............................... 642 Squizzato, A. ............................. 803 Stamer, K. ................................. 573 Stankiewicz, A. ........................ 1037 Steeghs, N................................. 146 Steffens, S................................. 714 Stellos, K. .................................. 974 Stocco, C................................... 245 Stockschlaeder, M..................... 496 Straub, A. .................................. 608 Street, A. ................................... 922 Strieter, R.M. ............................. 755 Strubel, G. ............................... 1046 Subramanyam, B................. 45, 847 Sudo, T...................................... 665 Sukovich, D. ................................ 45 Sullivan, M.E. ...................... 54, 847 Suvorava, T. .............................. 331 Szemraj, J. .............................. 1037 Sztukowska, M. ......................... 527 Taher, A.T. .............................. 1031 Tanaka, A.................................. 124 Tanaka, M. ................................ 795 Tanck, M.W.T. ........................... 181 Tanda, M. .................................. 803 Targher, G. .............................. 1059 Tejerina, T. ................................ 979 Tenchini, M.L............................. 546 Terzic, M.................................... 322 Thisyakorn, U. ........................... 627 Thomassen, S. ............................ 15 Thompson, A.R. ........................ 176 Thomssen, C. ............................ 503 Tick, L.W. .................................. 944 Tiemann, M. ............................ 1023 Toennes, S.W.......................... 1046 Tofteng, C.L............................... 234 Toga, K...................................... 665 Toh, C.-H................................... 161 Tomandl, B. ............................... 974 Tomita, T. .................................... 81 Tomkowski, W.Z........................ 191 Tomoike, H. ............................. 1052 Toth, O. ..................................... 435 Tracz, W.................................. 1056 Trujillo-Santos, J........................ 186

Tsai, M.Y. ..................................493 Tsibida, M. .................................683 Turpie, A.G.G. ...........................931 Uchiba, M. ...................................81 Ueland, T. ..................................748 Ueshima, S. ...............................795 Uitterlinden, A.G. .......................288 Ullmann, E.F..............................944 Undas, A....................................868 Undas, A..................................1056 Unkrig, V....................................856 van de Gevel, J. ........................617 van den Besselaar, A.M.H.P

. ......................................323, 856 van den Hurk, C.M.....................394 van den Meiracker, A.H. ............325 van der Heijden, J.F...................676 van der Hoeven, N.V. ................676 van der Meer, F.J.M...................323 van Diepen, A.C. .......................394 van Hoek, B. ..............................181 van Klink, R.C.J. ........................146 van Rooijen, M.............................15 van Tilburg, N.H.........................534 van Vliet, H.H.D.M. ....................325 Vannier, J.-P................................27 Varin, R........................................27 Vaughan, D.E. ...........................263 Venco, A. ...................................803 Vera, I.J. ....................................240 Verdy, E.....................................109 Vergona, R. ...................45, 54, 847 Vicente, V. .................................153 Vilahur, G...................................650 Vincelette, J. ..................45, 54, 847 Vlasveld, L.T..............................146 Vokó, Z. .....................................458 Völler, H.....................................310 vom Hagen, F. .............................99 von Auer, C................................228 von Hundelshausen, P...............704 Vormittag, R...............................573 Vos, H.L.....................................534 Vos, M. ......................................807 Vretenbrant, K. ..........................417 Vuissoz, J.-M. ............................890 Wagner, O. ................................880 Wagner, P....................................99 Wahi, M.M. ................................573 Wakefield, T.W. .........................400 Walton, K. ..................................974 Wang, D.L..................................658 Wang, G.-P................................830 Wang, W....................................839 Wang, Y.-X. ...................45, 54, 847 Washington, V.A........................955 Watson, S.P...............................814 Watzka, M..................................998 Watzke, H. .................................310 Weber, A.-A. ................................11 Weber, C. ..................685, 694, 979

Weber, H................................... 119 Weisbach, V.............................. 870 Weisel, J.W............................... 552 Weissmann, N........................... 774 Wells, P.S. ........................ 195, 635 Weltermann, A. ......................... 119 Wendel, H.P.............................. 608 Werker-van Gelder, L................ 146 Wessely, R.............................. 1003 White, A. ................................... 681 White, J.G. ................................ 202 Wilting, J. .................................. 763 Winsauer, G. ............................. 364 Wisniewska, J. .......................... 191 Witteman, J.C.M. ...................... 288 Wojta, J..................................... 385 Wolf, T. ..................................... 310 Wong, R.S.M............................. 866 Woollard, K. .............................. 681 Wrobleski, S.K. ......................... 400 Wu, H.-L.................................... 658 Wulff, K. .................................... 542 Xin, H.-Y. .................................. 830 Yamada, Y. ............................... 665 Yang, L. .................................... 899 Yiu, H.H.W. ............................... 866 Yndestad, A. ............................. 748 Yoshida, M. ............................... 124 You, J.H.S................................. 866 Yuan, S. .........................45, 54, 847 Zafar, M.U. ................................ 487 Zajkowski, P.J. .......................... 400 Zarrabeitia, R. ........................... 254 Zernecke, A............................... 730 Zhao, L.................................. 45, 54 Zhou, L...................................... 866 Zhu, G.-J. .................................. 839 Zhu, Z.-Q. ................................. 839 Zieliński, L. .............................. 1056 Ziemer, G.................................. 608 Zotz, R.B................................... 496 Zu, S.-Y..................................... 839 Zuo, Z. ...................................... 866

Documents

Index Vol. 97, 2007 Contents Keywords Authors · Index Vol. 97, 2007 Contents Keywords Authors ... Carl-Erik Dempfle, ... Non-homologous recombination associated with a shortened